跳至主要内容
临床试验/NL-OMON56658
NL-OMON56658尚未招募不适用

Chemosensitivity during phases of the menstrual cycle in breast cancer patients - Chemosense

ederlands Kanker Instituut0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • Women with a new diagnosis of triple negative breast cancer who have not yet
  • started systemic treatment.
  • Patients with stage I-III disease, patient with locoregional recurrence who
  • have not been treated with chemotherapy before.
  • Aged < 60 years
  • Women having a (regular) physiological menstrual cycle
  • Patients who are assigned to receive neoadjuvant chemotherapy with or without
  • immunotherapy, targeted therapy and endocrine therapy
  • Patients must be systemic treatment naïve for current malignancy (e.g. no
  • chemotherapy, hormonal therapy or targeted therapy)
  • Signed written informed consent

排除标准

  • - current use of hormonal contraception or in the six weeks prior to start of
  • neoadjuvant systemic treatment for breast cancer, either:
  • Oral contraception (OAC)
  • Hormonal intra-uterine device (IUD, Mirena)
  • No ovarian function suppression to preserve fertility
  • Other forms of hormonal contraception, including but not limited to:
  • nuva-ring, Implanon, prikpil
  • - currently pregnant and / or breast feeding. In case of use of hormonal
  • contraception or breast feeding in de last year: patients should have had at
  • least 2 menstrual cycles since stopping hormonal contraception.
  • - IVF-trajectory for egg cell preservation prior to start of neoadjuvant
  • systemic treatment
  • - Patients with known PCOS polycystic ovarian syndrome

研究者

发起方
ederlands Kanker Instituut

相似试验